Tonix plans 70-90 sales reps for TNX-102 SL if FDA approves fibromyalgia NDA

Tonix Pharmaceuticals Holding Corp.

Company plans to hire 70-90 sales representatives for TNX-102 SL conditional on FDA approval of NDA for fibromyalgia.
TNX-102 SL NDA is under FDA review; approval decision would trigger commercial launch planning.
Updated corporate presentation filed as Exhibit 99.01 for investor meetings; may contain nonpublic information.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.